Molecular structure of Prulifloxacin, CAS Number: 123447-62-1
Prulifloxacin (CAS 123447-62-1)
Alternate Names:
Quisnon; Pruvel
Application:
Prulifloxacin is a compound with broad spectrum antibacterial activity
CAS Number:
123447-62-1
Purity:
≥98%
Molecular Weight:
461.46
Molecular Formula:
C21H20FN3O6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Prulifloxacin is a broad-spectrum antibacterial agent that functions by inhibiting the bacterial DNA gyrase enzyme. This inhibition prevents the relaxation of supercoiled DNA, leading to the disruption of DNA replication and transcription processes in susceptible bacteria. As a result, prulifloxacin exerts its bactericidal effect by interfering with the cellular functions of the target microorganisms. By targeting the DNA gyrase enzyme, prulifloxacin disrupts the bacterial DNA replication machinery, ultimately leading to the inhibition of bacterial growth and proliferation. This mechanism of action makes prulifloxacin useful for studying the molecular processes involved in bacterial DNA replication and transcription, providing insights into the fundamental biological pathways of bacterial cells.
Prulifloxacin (CAS 123447-62-1) References
- Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice-The 'AIOLOS' Study. | Gourgoulianis, K., et al. 2021. Can Respir J. 2021: 6620585. PMID: 34122678
- Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates. | Zhou, W., et al. 2021. Front Microbiol. 12: 658637. PMID: 34276592
- Spatiotemporal profiling of antibiotics and resistance genes in a river catchment: Human population as the main driver of antibiotic and antibiotic resistance gene presence in the environment. | Elder, FCT., et al. 2021. Water Res. 203: 117533. PMID: 34416649
- Phenotypic and genotypic characterization of antimicrobial resistance in clinical isolates of Vibrio cholerae over a decade (2002-2016). | Gupta, P., et al. 2022. Indian J Med Microbiol. 40: 24-29. PMID: 34848326
- Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa. | She, P., et al. 2021. Curr Microbiol. 79: 12. PMID: 34905092
- Comparison of Fluoroquinolones and Other Antibiotic Prophylaxis Regimens for Preventing Complications in Patients Undergoing Transrectal Prostate Biopsy. | Tulone, G., et al. 2022. Antibiotics (Basel). 11: PMID: 35326878
- Antibiotic prophylaxis in patients who had undergone to prostate biopsy in between the EMA warning era: effects of fluoroquinolones in diabetic and non-diabetic patients. Results of an observational cohort study. | Bartoletti, R., et al. 2022. World J Urol. 40: 2025-2031. PMID: 35689105
- D-mannose for preventing and treating urinary tract infections. | Cooper, TE., et al. 2022. Cochrane Database Syst Rev. 8: CD013608. PMID: 36041061
- The Impact of Curcumin on Immune Response: An Immunomodulatory Strategy to Treat Sepsis. | Allegra, A., et al. 2022. Int J Mol Sci. 23: PMID: 36499036
- Effect of divalent and trivalent metal ions on artificial membrane permeation of fluoroquinolones. | Nakatani, N. and Sugano, K. 2022. ADMET DMPK. 10: 289-297. PMID: 36578565
- Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators: in vitro, molecular docking, molecular dynamics, and SAR studies. | Farouk, F., et al. 2023. J Enzyme Inhib Med Chem. 38: 2171029. PMID: 36701269
- A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects. | Shi, Z., et al. 2023. Molecules. 28: PMID: 36838752
- Combination drug strategies for biofilm eradication using synthetic and natural agents in KAPE pathogens. | Bari, AK., et al. 2023. Front Cell Infect Microbiol. 13: 1155699. PMID: 37139491
Inhibitor of:
Topo II.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Prulifloxacin, 250 mg | sc-204868 | 250 mg | $77.00 | |||
Prulifloxacin, 1 g | sc-204868A | 1 g | $416.00 |